Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Akero Therapeutics, Inc. (AKRO)
Last akero therapeutics, inc. earnings: 3/16 07:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
-- Phase 3 SYNCHRONY Histology and SYNCHRONY Real-World studies in patients with pre-cirrhotic MASH (F2-F3) continue to enroll; SYNCHRONY Outcomes study in patients with compensated cirrhosis due to MASH (F4) on track to be initiated in second quarter of 2024 -- SOUTH SAN FRANCISCO, Calif., May 10, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported first quarter financial results for the period ending March 31, 2024 and provided business updates. "We continued to make significant advancements in the clinical development of EFX during the first quarter of this year," said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. "The increased improvements in fibrosis stage observed from weeks 24 to 96 in the Phase 2b HARMONY study in patients with pre-cirrhotic MASH (F2-F3) showed EFX's poten
Show less
Read more
Impact Snapshot
Event Time:
AKRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKRO alerts
High impacting Akero Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKRO
News
- Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against Akero Therapeutics, Inc. (AKRO)Business Wire
- DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero TherapeuticsPR Newswire
- AKRO SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Reminds Akero Therapeutics, Inc. Investors to Join the Class Action LawsuitAccesswire
- AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKROAccesswire
- Lowey Dannenberg, P.C. is Investigating Akero Therapeutics, Inc. (“Akero”) (NASDAQ: AKRO) for Potential Violations of the Federal Securities Laws and Encourages Investors with Losses to Contact the FirmGlobeNewswire
AKRO
Earnings
- 11/13/23 - Miss
AKRO
Sec Filings
- 5/10/24 - Form S-3ASR
- 5/10/24 - Form 10-Q
- 5/10/24 - Form 8-K
- AKRO's page on the SEC website